Tomer Amit and Sonia Berrih-Aknin - Biotech Vs. Depression

<p class="p1"><span class="s1">Angel Scale Biotech: <a href= "https://syndicate.angelinvestboston.com/en-us/the-surge-of-opportunities-in-angel-scale-biotech"> Learn More</a></span></p> <p class="p1"><span class="s1">Tomer Amit and Sonia Berrih-Aknin, PhD founded PreciseMent Health to target treatments for depression and bipolar disorder guided by protein markers associated with good outcomes. The work promises to address the great uncertainties that exist in current treatment practices. Truly a mind-expanding conversation with a compelling team.</span></p> <p class="p2">Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson.</p> <p class="p1"><span class="s1">Highlights:</span></p> <ul class="ul1"> <li class="li3"><span class="s1">Sal Daher Introduces Tomer Amit and Sonia Berrih-Aknin, PhD</span></li> <li class="li3"><span class="s1">What PreciseMent Health is Solving</span></li> <li class="li3"><span class="s1">"...Basically, you had a database of patient data, where the patient's response to treatment had been recorded. Then you took blood samples, and you analyzed to see if there were proteins that indicated certain treatments being more likely to lead to successful treatment than others..."</span></li> <li class="li3"><span class="s1">"... Really, for the first time, we can say that we are identifying dependable biosignatures in the peripheral blood..."</span></li> <li class="li3"><span class="s1">Dealing With Side Effects</span></li> <li class="li3"><span class="s1">"... We'll make it more accessible because of the copay. The $2,000 has a $300 copay with it, which makes it very difficult for a lot of people to pay. We can go in a lot lower because our costs of goods sold are going to be lower ... We want to really have a huge change in the way that mental health is treated and diagnosed..."</span></li> <li class="li3"><span class="s1">Intellectual Property Protection</span></li> <li class="li3"><span class="s1">"...We're targeting initially the psychiatry mar